Gastrografin,(660 mg + 100 mg)/ml, oral and rectal solution
Meglumine amidotrizoate + Sodium amidotrizoate
Gastrografin is a contrast agent used exclusively for diagnostic purposes in radiological examinations, including computed tomography of the gastrointestinal tract.
The medicine is in the form of an oral or rectal solution. It facilitates imaging of narrowing, leakage, dilation of the colon, foreign bodies, tumors, etc.
Gastrografin is often used when a barium enema or paste cannot be used. Sometimes the medicine is used in combination with barium to increase diagnostic efficacy.
Gastrografin may also be used to treat meconium ileus.
Gastrografin facilitates the distinction between the intestines and adjacent anatomical structures and allows for the evaluation of changes in the shape of the pancreas.
Before starting to use Gastrografin, consult your doctor:
(enlargement of the thyroid gland), as iodine-containing contrast agents may induce hyperthyroidism and thyrotoxic crisis (a serious complication associated with hyperthyroidism) in such cases;
Tell your doctor about all the medicines you have taken recently, including those available without a prescription.
Be particularly careful when using Gastrografin with the following medicines:
Before starting the examination, it is recommended to empty the intestines. The doctor will inform the patient of this necessity.
Inform your doctor if you are pregnant or think you may be pregnant, as Gastrografin should be used with caution in pregnant women.
Inform your doctor if you are breastfeedingor plan to breastfeed. The doctor will decide on the possibility of breastfeeding.
There is no information on the effect of Gastrografin on the ability to drive vehicles or operate machinery.
Additional information
Gastrografincontains 3.76 mg of sodium (the main component of common salt) in each 1 ml, which corresponds to
0.19% of the maximum daily sodium intake recommended by the WHO for an adult.
Gastrografin is intended for oral or rectal use. The dose of Gastrografin is determined by the doctor. It depends on the patient's age and the type of X-ray examination.
Gastrografin must not be administered by injection.
Detailed information on dosing and administration is presented at the end of this leaflet.
Overdose of Gastrografin is unlikely. In case of overdose, the doctor will start treatment of the symptoms that occur. This may involve intravenous replenishment of water and electrolytes in the body.
Like all medicines, Gastrografin can cause side effects, although not everybody gets them.
Side effects are usually mild to moderate and are temporary. Severe and life-threatening reactions have also been reported, including death. The most common side effects are:
nausea, vomiting, diarrhea.
The following are possible side effects, grouped by frequency of occurrence:
Common | Rare | Unknown |
Vomiting Nausea Diarrhea | Pseudoallergic reactions, including severe cases (anaphylaxis) Hyperthyroidism Disorders of water and electrolyte balance, Disorders of consciousness Headache Dizziness Cardiac arrest Tachycardia (rapid heart rate) Anaphylaxis Decreased blood pressure Difficulty breathing (bronchospasm) Aspiration of the medicine into the respiratory tract Pulmonary edema following aspiration Aspiration pneumonia Dilation or perforation of the gastrointestinal tract Abdominal pain Blisters on the mucous membrane of the mouth | Hypothyroidism |
Common | Rare | Unknown |
Severe skin reactions with intense redness Exfoliative dermatitis Large blisters Hives Rash Itching Redness of the skin Facial swelling Fever Sweating |
As with other contrast agents, pseudoallergic reactionshave been reported, including severe reactions (anaphylaxis), which may require immediate medical intervention. The first symptoms of a severe reaction may be: mild facial swelling, lips, tongue, throat, coughing, itching, runny nose, sneezing, and hives.
Inform your doctor or medical staff if you experience any of the above symptoms or difficulty breathing.
Delayed reactionsmay occur several hours or days after administration of Gastrografin.
Gastrointestinal disorders:
Gastrografin may cause diarrhea, which resolves after bowel emptying. In patients with small intestine inflammation, temporary worsening of symptoms may occur. In case of constipation, prolonged contact with the intestinal mucosa may lead to ulceration and necrosis of the intestine.
If any of the symptoms worsen or other side effects occur,
including any not listed in this leaflet, inform your doctor or radiologist.
If you experience any side effects, including those not listed in this leaflet, please inform your doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products,
Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products,
Jerozolimskie Avenue 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309,
website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of the medicine.
Protect from light and X-ray radiation.
There are no special recommendations for the storage temperature of the medicinal product.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging.
The contents of the bottle should be used within 72 hours of opening.
Bayer AG
Kaiser-Wilhelm-Allee 1
51373 Leverkusen
Germany
Berlimed S.A.
Poligono Industrial Santa Rosa
c/ Francisco Alonso s/n
E-28806 Alcalá de Henares Madrid
Spain
To obtain more detailed information about this medicine, please contact the local representative of the marketing authorization holder:
Bayer Sp. z o.o.
Jerozolimskie Avenue 158
02-326 Warsaw, Poland
tel.: (0-22) 572-35-00
Date of last revision of the leaflet: March 2025
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.